SCHEDULE: Affinity Asset Advisors Discloses 5.8% Stake in First Tracks Biotherapeutics

Affinity Asset Advisors, LLC and Michael Cho have jointly reported beneficial ownership of 2,032,012 shares, representing 5.8% of First Tracks Biotherapeutics, Inc. common stock as of June 30, 2026.

Summary

• Affinity Asset Advisors, LLC, acting as the investment manager for Affinity Healthcare Fund, LP, and Michael Cho, the managing member of the Adviser, have disclosed their beneficial ownership of First Tracks Biotherapeutics, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially own 2,032,012 shares of common stock.
• This ownership stake represents approximately 5.8% of the Issuer's outstanding common stock.
• The percentage is based on 34,892,381 shares of common stock outstanding as of May 12, 2026, as reported in the Issuer's Form 10-Q filed on May 14, 2026.
• Affinity Asset Advisors, LLC holds sole voting and dispositive power over these shares.
• Michael Cho, as the managing member of the Adviser, may be deemed a beneficial owner of these shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, indicating a significant but not controlling stake by an investment entity, suggesting confidence in the company's future prospects without immediate takeover intentions.

Positives

• Significant stake acquired by an investment entity (Affinity Asset Advisors, LLC) and its managing member (Michael Cho), indicating confidence in the company.
• The reporting persons hold sole voting and dispositive power, suggesting a clear investment strategy.
• The filing is a Schedule 13G, which typically indicates passive investment rather than an attempt to control the company.

Negatives

• No specific financial performance data or operational updates are provided in this filing, as it is purely an ownership disclosure.
• The filing does not offer insights into the investment thesis or future plans of Affinity Asset Advisors, LLC.

Risks

• Market volatility could impact the value of the investment.
• Changes in the company's strategic direction or financial performance could affect the reporting persons' investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that the acquisition of a significant minority stake by an investment advisor like Affinity Asset Advisors is common in the biotechnology sector, often signaling a belief in the company's technology or market potential, but this filing does not provide specific details on the company's operations or pipeline.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by an institutional investor may be viewed positively, potentially indicating increased scrutiny and support for the company's value. However, it also means a larger portion of shares are held by a single entity.
• Management: May face increased attention from the reporting persons regarding company strategy and performance.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Affinity Asset Advisors, LLC and Michael Cho will file amendments to this statement on Schedule 13G as necessary to report any changes in beneficial ownership.
• The reporting persons will be responsible for the timely filing of such amendments and the completeness and accuracy of the information concerning them.

Key Dates

Keywords

First Tracks Biotherapeutics, Affinity Asset Advisors, Michael Cho, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Shareholder